AACR Releases Inaugural Pediatric Cancer Progress Report
More than 30 new drugs have been approved for pediatric cancer in the past 10 years, but progress has...
Search/Filter
Loading...
AACR Project GENIE Named a Winner of the 2025 Amazon Web Services Imagine Grant for Nonprofits
AI-powered, multilingual cancer research pipeline will accelerate the pace of global data curation and expand access to real-world clinical...
Award Recipients Announced for the 2025 San Antonio Breast Cancer Symposium
SAN ANTONIO – The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR), an SABCS cosponsor, will honor...
AACR Applauds Selection of Richard Pazdur, MD, as Director of the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration
PHILADELPHIA – The American Association for Cancer Research (AACR) today congratulated Richard Pazdur, MD, on his appointment as Director...
AACR Expresses Support for FDA’s Proposed Rule to Decrease Nicotine Content in Certain Combusted Tobacco Products
PHILADELPHIA – The American Association for Cancer Research (AACR) today released a policy statement in support of a rule proposed...
A Combination Treatment May Help Cut Lifelong Ibrutinib for Chronic Lymphocytic Leukemia
PHILADELPHIA – Adding the investigational antibody ianalumab (VAY736) to ibrutinib (Imbruvica) allowed some patients with chronic lymphocytic leukemia (CLL)...
Investigational Antibody-drug Conjugate Shows Clinical Benefit Against Previously Treated Small Cell Lung Cancer
Patients with brain metastasis experienced responses in the phase I clinical trial BOSTON – Zocilurtatug pelitecan (zoci), also known as ZL-1310, an...
Elironrasib May Overcome Resistance to Prior KRAS G12C Inhibition in Non-small Cell Lung Cancer
The small molecule KRAS inhibitor elironrasib targets the active GTP-bound form of KRAS G12C and led to encouraging responses...
New Targeted Therapy Shows Promise for Patients With Advanced Bladder Cancer
BOSTON – FX-909, a first-in-class investigational oral small molecule inhibitor of peroxisome proliferator-activated receptor gamma (PPARG), showed early signs...
Zenocutuzumab Shows Clinical Benefit in Rare Bile Duct Cancer
BOSTON – Zenocutuzumab (Bizengri), a bispecific antibody that targets human epidermal growth factor receptor 2 (HER2) and HER3, led...